Sagent Pharmaceuticals, Inc. Announces the Launch of Vancomycin Hydrochloride for Injection, USP

SCHAUMBURG, Ill., Sept. 28, 2012 (GLOBE NEWSWIRE) -- Sagent Pharmaceuticals, Inc. (Nasdaq:SGNT) today announced the launch of Vancomycin Hydrochloride for Injection, USP, an anti-infective, in a 5 gram pharmacy bulk package presentation. According to IMS, for the 12 months ending June 2012, the US market for Vancomycin Hydrochloride for Injection, USP approximated $186 million of which about fifty percent of the sales was pharmacy bulk packages. As with all products in Sagent's portfolio, Vancomycin features the company's PreventIV MeasuresSM packaging and labeling, designed to help reduce medication errors.